Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93812 | 0.83 | GAA (0.49) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| SCHEMBL12464695 | 0.83 | FAAH (0.46) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| SCHEMBL15468358 | 0.82 | CASP2 (0.53) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| Hydrochloric Acid SCHEMBL93987 | 0.81 | GAA (0.48) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| SCHEMBL24626058 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| SCHEMBL11028511 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2D6GAACYP3A4ALDH1A1 | |
| SCHEMBL10900410 | 0.79 | DNM1 (0.61) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| SCHEMBL3550590 | 0.79 | GAA (0.49) | CYP1A2CYP2D6GAACYP3A4DNM1 | |
| Hydrochloric Acid SCHEMBL5041929 | 0.79 | CYP3A4 (0.50) | CYP1A2CYP2D6GAACYP3A4ALDH1A1 | |
| SCHEMBL474196 | 0.78 | KMT2A (0.56) | CYP1A2CYP2D6GAACYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344858-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344859-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-9884121-B2 | Biomaterials and a method for making and using same | ALUMEND, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9855337-B2 | Biomaterials and a method for making and using the same | ALUMEND, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160175449-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2114370-B1 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | ALLERGAN INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252771-B2 | A modified chitosan and a prostaglandin, prostamide, non-steroidal anti-inflammatory drug, or a corticosteroid; opthalmic drug delivery solution; improved bioavailability | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2425816-A2 | A pharmaceutical composition for use in treating an ocular disease or condition and a method for producing the composition | Allergan, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2114370-A2 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | Allergan, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080207561-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALLERGAN, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200948-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | PHOTOBIOMED CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008094659-A2 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | ALLERGAN, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200948-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | CYP1A2 2359/4885CYP2D6 1698/4885GAA 47/4885 |
| US-20180344859-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | CYP1A2 2359/4885CYP2D6 1698/4885GAA 47/4885 |
| US-20180344858-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | CYP1A2 2359/4885CYP2D6 1698/4885GAA 47/4885 |
| US-20160175449-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | CYP1A2 2359/4885CYP2D6 1698/4885GAA 47/4885 |
| US-20080207561-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | PTGES, PTGES2, PTGIS | CYP1A2 1366/4885CYP2D6 2596/4885GAA 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.